VBL Therapeutics: Rises on positive data from multiple sclerosis treatment trial

Notable Labs

11/09/2020 14:38

** U.S.-listed shares of Israel-based drug developer
 VBLT.O  rise 22.8% to $1.4; set for best day in almost 6 months
    ** Stock among most actively-traded across U.S. exchanges
    ** Co says its experimental monoclonal antibodies to treat
multiple sclerosis showed response in patients, regardless of
disease severity  urn:newsml:reuters.com:*:nGNXqtPjf
    ** The antibodies significantly prevented monocytes, which
have been associated with making the disease worsen, from
migrating
    ** Co says it aims to start human trials of its lead
candidate VB-601 in H2 2021 
    ** Up to Thursday's close, stock fell 5% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))